Theravance Biopharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Theravance Biopharma Inc.
Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology
Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.
Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension
Ampreloxetine failed in a Phase III trial in 2021, but the company will start a registrational trial by the end of Q1 for the drug in the multiple system atrophy population, where it has shown efficacy.
On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
Financing Quarterly Statistics, Q3 2022
During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Theravance Biopharma Ireland Limited
- Theravance Biopharma US, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.